AEON Biopharma, Inc.

AEON Biopharma, Inc. (AEON) is a clinical-stage biopharmaceutical company that entered public markets through a SPAC merger with Priveterra Acquisition Corp, sponsored by Priveterra Sponsor LLC, a healthcare-focused blank-check vehicle that completed its IPO in 2021. The company is advancing a pipeline of botulinum toxin complex therapeutics targeting therapeutic indications including migraine and cervical dystonia. AEON filed an 8-K current report with the SEC on January 21, 2026, continuing its post-merger public company disclosure obligations in the life sciences and biopharma sector. For full filing history, deal analytics, and real-time data on AEON Biopharma and the broader SPAC market, sign up for access at SpacDesk.